SG11201705361PA - Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease - Google Patents
Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver diseaseInfo
- Publication number
- SG11201705361PA SG11201705361PA SG11201705361PA SG11201705361PA SG11201705361PA SG 11201705361P A SG11201705361P A SG 11201705361PA SG 11201705361P A SG11201705361P A SG 11201705361PA SG 11201705361P A SG11201705361P A SG 11201705361PA SG 11201705361P A SG11201705361P A SG 11201705361PA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- combination therapy
- liver disease
- fatty liver
- alcoholic fatty
- Prior art date
Links
- 229940121373 acetyl-coa carboxylase inhibitor Drugs 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562101726P | 2015-01-09 | 2015-01-09 | |
| PCT/US2016/012673 WO2016112305A1 (fr) | 2015-01-09 | 2016-01-08 | Thérapie combinée à base d'un inhibiteur de l'acc utilisable en vue du traitement de la stéatose hépatique non alcoolique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201705361PA true SG11201705361PA (en) | 2017-08-30 |
Family
ID=56356482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201705361PA SG11201705361PA (en) | 2015-01-09 | 2016-01-08 | Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20180021341A1 (fr) |
| EP (2) | EP3597271A1 (fr) |
| JP (2) | JP2018501276A (fr) |
| KR (1) | KR20170102299A (fr) |
| CN (1) | CN107106873A (fr) |
| AU (1) | AU2016205138A1 (fr) |
| BR (1) | BR112017014341A2 (fr) |
| CA (1) | CA2972919A1 (fr) |
| EA (2) | EA201892625A1 (fr) |
| HK (2) | HK1243369A1 (fr) |
| MX (1) | MX2017008844A (fr) |
| SG (1) | SG11201705361PA (fr) |
| WO (1) | WO2016112305A1 (fr) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2635581C (fr) | 2005-12-28 | 2017-02-28 | Vertex Pharmaceuticals Incorporated | Formes solides de n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoleine-3-carboxamide |
| TWI598347B (zh) | 2009-07-13 | 2017-09-11 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
| US9719068B2 (en) | 2010-05-06 | 2017-08-01 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into intestinal tissues through directed differentiation |
| EP2545964A1 (fr) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Nouveaux composés se liant au fxr (nr1 h4) et modulant son activité |
| US11571431B2 (en) | 2013-12-04 | 2023-02-07 | Galmed Research And Development Ltd | Aramchol salts |
| US10174289B2 (en) | 2014-05-28 | 2019-01-08 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into gastric tissues through directed differentiation |
| CA2963704A1 (fr) | 2014-10-17 | 2016-04-21 | Children's Hospital Medical Center | Modele in vivo d'intestin grele humain faisant intervenir des cellules souches pluripotentes et ses procedes de fabrication et d'utilisation |
| PT3191470T (pt) | 2015-07-06 | 2019-06-05 | Gilead Sciences Inc | Moduladores de cot e métodos para a sua utilização |
| EP3380478B1 (fr) | 2015-11-25 | 2020-12-23 | Gilead Apollo, LLC | Inhibiteurs de l'acc à base d'esters et utilisations associées |
| EA201890913A1 (ru) * | 2015-11-25 | 2018-11-30 | Джилид Аполло, Ллс | Пиразоловые соединения в качестве ингибиторов акк и их применение |
| IL243707A0 (en) | 2016-01-20 | 2016-05-01 | Galmed Res And Dev Ltd | Treatment to regulate the microbiota in the intestine |
| AU2017226267B2 (en) | 2016-03-02 | 2021-06-24 | Gilead Apollo, Llc | Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof |
| CA3016641A1 (fr) | 2016-05-05 | 2017-11-09 | Children's Hospital Medical Center | Procedes de fabrication in vitro de tissu de fundus d'estomac et compositions associees a celui-ci |
| PL3730487T3 (pl) | 2016-06-13 | 2022-08-16 | Gilead Sciences, Inc. | Pochodne azetydyny jako modulatory fxr (nr1h4) |
| CA3252823A1 (fr) | 2016-06-13 | 2025-02-25 | Gilead Sciences, Inc. | Composés de modulation fxr (nr1h4) |
| AU2017353982B2 (en) | 2016-11-04 | 2021-05-06 | Children's Hospital Medical Center | Liver organoid compositions and methods of making and using same |
| US20190275061A1 (en) * | 2016-11-10 | 2019-09-12 | Galmed Research And Development Ltd | Inhibition of fibrosis in non alcohol fatty liver disease patients |
| WO2018087599A1 (fr) * | 2016-11-10 | 2018-05-17 | Galmed Research And Development Ltd. | Traitement de la fibrose |
| US11197870B2 (en) | 2016-11-10 | 2021-12-14 | Galmed Research And Development Ltd | Treatment for hepatic fibrosis |
| WO2018106628A1 (fr) | 2016-12-05 | 2018-06-14 | Children's Hospital Medical Center | Organoïdes du côlon et leurs procédés de préparation et d'utilisation |
| JP7300394B2 (ja) | 2017-01-17 | 2023-06-29 | ヘパリジェニックス ゲーエムベーハー | 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害 |
| CN108341830B (zh) * | 2017-01-22 | 2021-03-02 | 广东东阳光药业有限公司 | 噻吩并嘧啶衍生物及其在药物中的应用 |
| WO2018171699A1 (fr) * | 2017-03-24 | 2018-09-27 | 浙江海正药业股份有限公司 | Dérivés substitués par un hétéroaryle et une pyrimidinone, leur procédé de préparation et leur application |
| WO2018183342A1 (fr) * | 2017-03-28 | 2018-10-04 | Gilead Sciences, Inc. | Méthodes de traitement d'une maladie hépatique |
| EP4122464B1 (fr) * | 2017-03-28 | 2024-05-15 | Gilead Sciences, Inc. | Combinaisons thérapeutiques pour le traitement des maladies du foie |
| TW201902478A (zh) * | 2017-04-12 | 2019-01-16 | 美商基利科學股份有限公司 | 治療肝臟疾病之方法 |
| WO2018191673A1 (fr) | 2017-04-14 | 2018-10-18 | Children's Hospital Medical Center | Compositions de cellules souches issues de multiples cellules donneuses et leurs procédés de préparation |
| WO2018193006A1 (fr) * | 2017-04-18 | 2018-10-25 | Genfit | Combinaison d'elafibranor ou de dérivés de celui-ci avec un agent anti-nash, anti-fibrotique ou anti-cholestatique |
| US11583570B2 (en) * | 2017-04-24 | 2023-02-21 | Tsinghua University | Use of autoinducer-related pathway in inducing apoptosis and anti-infective therapy |
| JP2020524181A (ja) * | 2017-06-19 | 2020-08-13 | アリーナ ファーマシューティカルズ， インコーポレイテッド | Ｎａｆｌｄおよびｎａｓｈの治療のための化合物および方法 |
| US10995099B2 (en) | 2017-07-17 | 2021-05-04 | Nanjing Ruijie Pharmatech Co., Ltd. | Compounds and their uses as ACC inhibitors |
| EP3660023B1 (fr) * | 2017-07-26 | 2023-03-08 | Nanjing Sanhome Pharmaceutical Co., Ltd. | Composés de thiénopyrimidinedione utilisés en tant qu'inhibiteurs d'acc et leur utilisation |
| CN109316601B (zh) * | 2017-07-31 | 2021-11-09 | 武汉朗来科技发展有限公司 | 药物组合物及其用途 |
| EP3676262A4 (fr) | 2017-09-03 | 2021-03-31 | Angion Biomedica Corp. | Hétérocycles vinyliques utilisés en tant qu'inhibiteurs de la kinase bispiralée associée à rho (rock) |
| US11033601B2 (en) * | 2017-09-14 | 2021-06-15 | The Regents Of The University Of Colorado, A Body Corporate | Selective inhibition of V1b for treating fatty liver |
| US10980810B2 (en) * | 2017-10-06 | 2021-04-20 | Gilead Sciences, Inc. | Combination therapy comprising an ACC inhibitor |
| US12297457B2 (en) | 2017-10-10 | 2025-05-13 | Children's Hospital Medical Center | Esophageal tissue and/or organoid compositions and methods of making same |
| CN114920818B (zh) * | 2017-11-06 | 2024-02-27 | 深圳市图微安创科技开发有限公司 | 基于胃泌酸调节素类似物glp-1r/gcgr双靶点激动剂多肽治疗胆汁性肝硬化 |
| CN107693514A (zh) * | 2017-12-04 | 2018-02-16 | 威海贯标信息科技有限公司 | 一种鲁格列净组合物 |
| EP3727394A4 (fr) | 2017-12-21 | 2021-09-08 | Children's Hospital Medical Center | Organoïdes humains numérisés et méthodes d'utilisation de ceux-ci |
| WO2019149738A1 (fr) | 2018-01-31 | 2019-08-08 | Heparegenix Gmbh | Inhibiteurs de protéine kinase mkk4 pour favoriser la régénération hépatique ou pour réduire ou prévenir la mort des hépatocytes |
| AU2019254371A1 (en) * | 2018-04-17 | 2020-10-08 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| JP2021522247A (ja) * | 2018-04-24 | 2021-08-30 | ピーエイチ・ファーマ・カンパニー・リミテッドＰｈ Ｐｈａｒｍａ Ｃｏ．， Ｌｔｄ． | 肝疾患における好中球エラスターゼ阻害薬の使用 |
| US11731968B2 (en) | 2018-06-21 | 2023-08-22 | Heparegenix Gmbh | Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| CA3104246A1 (fr) | 2018-07-16 | 2020-01-23 | Heparegenix Gmbh | Inhibiteurs de proteine kinase permettant de favoriser la regeneration du foie, ou de reduire ou de prevenir la mort des hepatocytes |
| KR20250163421A (ko) | 2018-07-26 | 2025-11-20 | 칠드런즈 호스피탈 메디칼 센터 | 간-담도-췌장 조직 및 이를 제조하는 방법 |
| JP2022514731A (ja) * | 2018-08-14 | 2022-02-15 | アヴォリント | 原発性硬化性胆管炎の処置方法 |
| BR112021003039A2 (pt) | 2018-08-31 | 2021-05-18 | Pfizer Inc. | combinações para o tratamento de nash/nafld e doenças relacionadas |
| KR102876077B1 (ko) * | 2018-09-06 | 2025-10-23 | 갈메드 리서치 앤드 디벨롭먼트 리미티드 | 간 질환을 치료하기 위한 병용 요법 |
| CN112823012A (zh) | 2018-09-12 | 2021-05-18 | 儿童医院医学中心 | 用于产生造血干细胞及其衍生物的类器官组合物 |
| CN110950884B (zh) * | 2018-09-27 | 2024-03-26 | 上海翰森生物医药科技有限公司 | 含二并环类衍生物抑制剂、其制备方法和应用 |
| KR20210093947A (ko) * | 2018-11-20 | 2021-07-28 | 더 내셔널 인스티튜츠 오브 파마슈티컬 리서치 앤드 디벨롭먼트 (엔아이피) | 스피로 화합물 및 이의 의학적 용도 |
| PE20211907A1 (es) | 2019-01-15 | 2021-09-28 | Gilead Sciences Inc | Compuestos moduladores de fxr (nr1h4) |
| CA3233305A1 (fr) | 2019-02-19 | 2020-08-27 | Gilead Sciences, Inc. | Formes solides d'agonistes de fxr |
| US12458612B2 (en) * | 2019-04-10 | 2025-11-04 | Genfit | Combination therapy comprising compounds of formula (I) and GLP-1 receptor agonists |
| AU2020267576B2 (en) | 2019-05-08 | 2025-03-13 | Aligos Therapeutics, Inc. | Modulators of THR-β and methods of use thereof |
| EP3976066A4 (fr) | 2019-05-31 | 2023-06-28 | Children's Hospital Medical Center | Procédés de production et de multiplication de cellules souches hématopoïétiques |
| TWI770527B (zh) | 2019-06-14 | 2022-07-11 | 美商基利科學股份有限公司 | Cot 調節劑及其使用方法 |
| CN113924303B (zh) * | 2019-07-02 | 2023-10-20 | 广东东阳光药业股份有限公司 | 具有立体构型的噻吩并嘧啶衍生物及其在药物中的应用 |
| CN114269745B (zh) | 2019-07-29 | 2025-04-22 | 海帕瑞吉尼克斯股份有限公司 | 用于促进肝再生或减少或预防肝细胞死亡的杂芳基取代的吡唑并吡啶蛋白激酶抑制剂 |
| AR119594A1 (es) | 2019-08-09 | 2021-12-29 | Gilead Sciences Inc | Derivados de tienopirimidina como inhibidores acc y usos de los mismos |
| CN110628810B (zh) * | 2019-08-13 | 2022-06-28 | 浙江大学 | 一种提高植物光合效率的方法 |
| WO2021040440A1 (fr) * | 2019-08-30 | 2021-03-04 | (주)셀트리온 | Composition pharmaceutique pour le traitement ou la prévention de la stéatohépatite non alcoolique (shna) |
| US20230105984A1 (en) | 2019-12-23 | 2023-04-06 | Svetlana Marukian | Compositions and methods for the treatment of liver diseases and disorders |
| ES2984974T3 (es) | 2020-01-15 | 2024-10-31 | Heparegenix Gmbh | Derivados de 3-benzoil-1H-pirrolo[2,3-b]piridina como inhibidores de MKK4 para el tratamiento de hepatopatías |
| JP2021134211A (ja) | 2020-02-24 | 2021-09-13 | ファイザー・インク | Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ |
| JP2022058085A (ja) | 2020-02-24 | 2022-04-11 | ファイザー・インク | ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ |
| KR102538047B1 (ko) * | 2020-03-11 | 2023-05-30 | 동아에스티 주식회사 | 비알콜성지방간염의 예방 또는 치료를 위한 약학적 조성물 |
| KR20220161438A (ko) | 2020-03-30 | 2022-12-06 | 길리애드 사이언시즈, 인코포레이티드 | Cot 억제제 화합물, (S)-6-(((1-(바이사이클로[1.1.1]펜탄-1-일)-1H-1,2,3-트라이아졸-4-일)2-메틸-1-옥소-1,2-다이하이드로아이소퀴놀린-5-일)메틸)))아미노8-클로로-(네오펜틸아미노)퀴놀린-3-카르보니트릴의 고체 형태 |
| WO2021202688A1 (fr) | 2020-04-02 | 2021-10-07 | Gilead Sciences, Inc. | Procédé de préparation d'un composé inhibiteur de cot |
| CN111407892A (zh) * | 2020-04-08 | 2020-07-14 | 中国药科大学 | Acsl4及其在nash中的应用 |
| US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
| CN115666558A (zh) | 2020-05-21 | 2023-01-31 | 盐野义制药株式会社 | 脂肪性肝病的治疗用药物 |
| EP4000616A1 (fr) * | 2020-11-17 | 2022-05-25 | Inventiva | Thérapie combinée pour le traitement d'une maladie du foie |
| WO2022192428A1 (fr) | 2021-03-11 | 2022-09-15 | Gilead Sciences, Inc. | Composés modulateurs de glp-1r |
| KR20230158542A (ko) | 2021-03-29 | 2023-11-20 | 길리애드 사이언시즈, 인코포레이티드 | Khk 억제제 |
| TW202304435A (zh) | 2021-06-04 | 2023-02-01 | 美商基利科學股份有限公司 | 治療ｎａｓｈ之方法 |
| TW202311256A (zh) | 2021-06-18 | 2023-03-16 | 美商基利科學股份有限公司 | 用於治療ｆｘｒ誘發之搔癢之ｉｌ－３１調節劑 |
| US20250006331A1 (en) * | 2021-08-31 | 2025-01-02 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Quantitative systems pharmacology methods for identifying therapeutics for disease states |
| WO2023047203A1 (fr) * | 2021-09-25 | 2023-03-30 | Torrent Pharmaceuticals Ltd | Combinaison d'omzotirome et d'agent antidiabétique, agent antihypertenseur ou agent anti-dyslipidémique |
| EP4434520A4 (fr) | 2021-11-19 | 2025-10-29 | Shionogi & Co | Produit pharmaceutique pour le traitement d'une maladie cardiaque ou d'une maladie du muscle squelettique |
| US20250017938A1 (en) * | 2023-06-20 | 2025-01-16 | Sagimet Biosciences Inc. | Combination therapies of fasn inhibitors with thyroid hormone receptor agonists |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110288114A1 (en) * | 2008-06-20 | 2011-11-24 | Kinemed, Inc. | Compositions for the treatment of fibrotic diseases or conditions |
| US20100113473A1 (en) * | 2008-10-30 | 2010-05-06 | Player Mark R | Aryl amide compound as an acetyl coenzyme a carboxylase inhibitor |
| WO2012090219A2 (fr) * | 2010-12-31 | 2012-07-05 | Jubilant Biosys Ltd. | COMPOSÉS THIAZOLES UTILES COMME INHIBITEURS DE L'ACÉTYL-CoA CARBOXYLASE (ACC) |
| KR102033806B1 (ko) * | 2011-11-11 | 2019-10-17 | 길리어드 아폴로, 엘엘씨 | Ａｃｃ 억제제 및 이의 용도 |
| WO2014182950A1 (fr) | 2013-05-10 | 2014-11-13 | Nimbus Apollo, Inc. | Inhibiteurs de l'acc et utilisations associées |
| HK1221411A1 (zh) * | 2013-05-10 | 2017-06-02 | Gilead Apollo, Inc. | Acc抑制剂和其用途 |
| EA201591959A1 (ru) * | 2013-05-10 | 2016-03-31 | Нимбус Аполло, Инк. | Ингибиторы акк и их применение |
| KR20160005365A (ko) * | 2013-05-10 | 2016-01-14 | 님버스 아폴로, 인코포레이티드 | Acc 억제제 및 이의 용도 |
-
2016
- 2016-01-08 BR BR112017014341-0A patent/BR112017014341A2/pt not_active Application Discontinuation
- 2016-01-08 WO PCT/US2016/012673 patent/WO2016112305A1/fr not_active Ceased
- 2016-01-08 EA EA201892625A patent/EA201892625A1/ru unknown
- 2016-01-08 SG SG11201705361PA patent/SG11201705361PA/en unknown
- 2016-01-08 EA EA201791258A patent/EA201791258A1/ru unknown
- 2016-01-08 EP EP19176040.4A patent/EP3597271A1/fr not_active Withdrawn
- 2016-01-08 HK HK18102859.6A patent/HK1243369A1/zh unknown
- 2016-01-08 CN CN201680004801.2A patent/CN107106873A/zh active Pending
- 2016-01-08 HK HK18105783.0A patent/HK1246232A1/zh unknown
- 2016-01-08 JP JP2017535411A patent/JP2018501276A/ja not_active Withdrawn
- 2016-01-08 AU AU2016205138A patent/AU2016205138A1/en not_active Abandoned
- 2016-01-08 CA CA2972919A patent/CA2972919A1/fr not_active Abandoned
- 2016-01-08 KR KR1020177021086A patent/KR20170102299A/ko not_active Withdrawn
- 2016-01-08 US US15/541,008 patent/US20180021341A1/en not_active Abandoned
- 2016-01-08 MX MX2017008844A patent/MX2017008844A/es unknown
- 2016-01-08 EP EP16735485.1A patent/EP3242722A4/fr not_active Withdrawn
-
2019
- 2019-05-13 US US16/410,894 patent/US20190381045A1/en not_active Abandoned
-
2020
- 2020-04-15 JP JP2020072689A patent/JP2020109130A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EA201791258A1 (ru) | 2017-12-29 |
| BR112017014341A2 (pt) | 2018-03-27 |
| JP2020109130A (ja) | 2020-07-16 |
| US20180021341A1 (en) | 2018-01-25 |
| AU2016205138A1 (en) | 2017-07-13 |
| HK1246232A1 (zh) | 2018-09-07 |
| JP2018501276A (ja) | 2018-01-18 |
| EP3242722A4 (fr) | 2018-07-11 |
| MX2017008844A (es) | 2018-03-14 |
| KR20170102299A (ko) | 2017-09-08 |
| HK1243369A1 (zh) | 2018-07-13 |
| EP3597271A1 (fr) | 2020-01-22 |
| EP3242722A1 (fr) | 2017-11-15 |
| CN107106873A (zh) | 2017-08-29 |
| US20190381045A1 (en) | 2019-12-19 |
| EA201892625A1 (ru) | 2019-07-31 |
| WO2016112305A1 (fr) | 2016-07-14 |
| CA2972919A1 (fr) | 2016-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201705361PA (en) | Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease | |
| IL253945A0 (en) | kdm1a inhibitors to treat the disease | |
| IL259133A (en) | Jamkaban combinations for the treatment of cardiovascular disease | |
| IL254722A0 (en) | Indoleamine 3,2-dioxygenase inhibitors for cancer treatment | |
| GB201411467D0 (en) | 7-hydroxy cannabidiol (7-oh-cbd) for use in the treatment of non-alcoholic fatty liver disease (nafld) | |
| ZA201607740B (en) | Treatment of the complications of chronic liver disease with caspase inhibitors | |
| HUE051654T2 (hu) | Készítmény akné kezelésére | |
| IL254266A0 (en) | Glucosylceramide synthase inhibitors for the treatment of diseases | |
| SG11202102684VA (en) | Treatment for non-alcoholic fatty liver disease | |
| EP3132795A4 (fr) | Composition pour la prévention ou le traitement de maladies hépatiques graisseuses | |
| EP3362053A4 (fr) | Traitement de la maladie du foie gras non alcoolique ou de la stéatohépatite non alcoolique avec de la 6-mercaptopurine à libération retardée | |
| ZA201805080B (en) | Application of triacetyl-3-hydroxyphenyladenosine in preparation of pharmaceutical drug for preventing or treating non-alcoholic fatty liver disease | |
| GB201506654D0 (en) | Formulations for inhibition of PCSK9 for the treatment of hypercholesterolemia | |
| PL3484475T3 (pl) | 1-Metylonikotynamid do leczenia choroby układu krążenia | |
| SI3302523T1 (sl) | Sestavek za zdravljenje tkivnih lezij | |
| PL3233074T3 (pl) | Leczenie niealkoholowych stłuszczeniowych chorób wątroby | |
| PT3340975T (pt) | Formulação para o tratamento de acne | |
| ZA201706986B (en) | Compositions for the treatment of kidney and/or liver disease | |
| IL257689B (en) | Pharmaceutical preparations and methods for treating diseases related to lack of oxygen | |
| GB201622116D0 (en) | Treatment of liver disease | |
| HK1259460A1 (en) | Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine | |
| HK1236868A1 (en) | Combination of an omega-3 fatty acid and an sglt-2 inhibitor for treating diseases of the liver | |
| HK1259743A1 (en) | Gemcabene combinations for the treatment of cardiovascular disease | |
| PL3273997T3 (pl) | Kompozycja do leczenia nieżytu nosa | |
| HK1247584A1 (zh) | 結晶c21h22c12n4o2丙二酸酯 |